Results 51 to 60 of about 6,322,056 (300)
Widening the spectrum of players affected by genetic changes in Wilms tumor relapse
iScienceSummary: Few studies investigated the genetics of relapsed Wilms tumor (WT), suggesting the SIX1 gene, the microRNA processing genes, and the MYCN network as possibly involved in a relevant percentage of relapses. We investigated 28 relapsing WT patients
Sara Ciceri +16 more
doaj +1 more source
Heliyon, 2017 Methotrexate (MTX) is the most used drug in rheumatoid arthritis (RA) treatment. However, it shows variability in clinical response, which is explained by an association with genetic polymorphisms.
Lilya M. Berkani +5 more
doaj +1 more source
Genetic risk model for in-stent restenosis of second-and third-generation drug-eluting stents
iScience, 2021 Summary: The new generation, i.e., second- and third-generation, drug-eluting stents (DESs) remain a risk of in-stent restenosis (ISR). We evaluated the power of a genetic risk score (GRS) model to identify high-risk populations for new generation DES ...
Yen-Wen Liu +11 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Allogeneic hematopoietic stem cell transplantation (alloHSCT) is an essential therapy for several malignant and nonmalignant diseases, but relapse and graft loss remain the principal threats to its success. Routine monitoring of chimerism and minimal residual disease (MRD) enables early detection of imminent recurrence and guides ...
Carmen Junk +10 more
wiley +1 more source
Empowerment: Qualitative underpinning of a new clinical genetics-specific patient-reported outcome [PDF]
, 2010 Recent qualitative research developed a new construct labelled Empowerment describing a new patient outcome from using clinical genetics services that included four dimensions: Knowledge and Understanding, Decision-Making, Instrumentality and Future ...
Dunn, Graham +6 more
core +1 more source
Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin +17 more
wiley +1 more source
The Clinical Genetics of Prostate Cancer
Hereditary Cancer in Clinical Practice, 2004 Prostate cancer is the most common cancer in men and the second highest cause of cancer-related mortality in the U.K. A genetic component in predisposition to prostate cancer has been recognized for decades.
Kommu Sashi +2 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Numerous international studies have reported declines in new cancer diagnoses, delayed diagnoses and disruptions in cancer treatment following the implementation of COVID‐19 pandemic public health measures, raising concerns that these effects may ultimately contribute to increased cancer mortality.
Friederike Erdmann +8 more
wiley +1 more source
Genetics in clinical practice: general practitioners' educational priorities in European countries
, 2008 PURPOSE: To assess how general practitioners (GPs) from European countries prioritized their genetic educational needs according to their geographic, sociodemographic, and educational characteristics.
Schmidtke, Joerg +41 more
core +1 more source
Gynecologic Oncology ReportsObjectives: As the need for clinical cancer genetics services continues to rise, health systems must strategize on how best to deliver this specialized care.
Tamar Nicole Soussana +6 more
doaj +1 more source